Myriad Genetics (MYGN) Competitors $13.74 +0.09 (+0.66%) (As of 01:00 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MYGN vs. ALKS, FOLD, LGND, GERN, MNKD, DVAX, CLDX, BCRX, NVAX, and INVAShould you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Alkermes (ALKS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Geron (GERN), MannKind (MNKD), Dynavax Technologies (DVAX), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), and Innoviva (INVA). These companies are all part of the "biotechnology" industry. Myriad Genetics vs. Alkermes Amicus Therapeutics Ligand Pharmaceuticals Geron MannKind Dynavax Technologies Celldex Therapeutics BioCryst Pharmaceuticals Novavax Innoviva Myriad Genetics (NASDAQ:MYGN) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Do insiders and institutionals hold more shares of MYGN or ALKS? 99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 2.1% of Myriad Genetics shares are held by company insiders. Comparatively, 4.9% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to MYGN or ALKS? In the previous week, Myriad Genetics had 3 more articles in the media than Alkermes. MarketBeat recorded 7 mentions for Myriad Genetics and 4 mentions for Alkermes. Alkermes' average media sentiment score of 1.38 beat Myriad Genetics' score of 0.26 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Alkermes 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, MYGN or ALKS? Myriad Genetics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Does the MarketBeat Community prefer MYGN or ALKS? Alkermes received 229 more outperform votes than Myriad Genetics when rated by MarketBeat users. Likewise, 70.51% of users gave Alkermes an outperform vote while only 52.99% of users gave Myriad Genetics an outperform vote. CompanyUnderperformOutperformMyriad GeneticsOutperform Votes46952.99% Underperform Votes41647.01% AlkermesOutperform Votes69870.51% Underperform Votes29229.49% Is MYGN or ALKS more profitable? Alkermes has a net margin of 22.15% compared to Myriad Genetics' net margin of -14.09%. Alkermes' return on equity of 24.92% beat Myriad Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Myriad Genetics-14.09% -4.51% -3.07% Alkermes 22.15%24.92%14.55% Which has better earnings & valuation, MYGN or ALKS? Alkermes has higher revenue and earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMyriad Genetics$823.60M1.51-$263.30M-$1.30-10.50Alkermes$1.51B3.17$355.76M$1.9515.13 Do analysts recommend MYGN or ALKS? Myriad Genetics presently has a consensus target price of $24.27, suggesting a potential upside of 77.82%. Alkermes has a consensus target price of $35.42, suggesting a potential upside of 20.06%. Given Myriad Genetics' higher probable upside, equities analysts clearly believe Myriad Genetics is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Myriad Genetics 3 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.00Alkermes 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.58 SummaryAlkermes beats Myriad Genetics on 14 of the 18 factors compared between the two stocks. Ad Prosper Trading AcademyA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading system finds high-probability option trades in less than 60 seconds a dayClick HERE to access this powerful AI Trading System Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYGN vs. The Competition Export to ExcelMetricMyriad GeneticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.24B$2.43B$5.20B$9.14BDividend YieldN/A0.76%5.12%4.28%P/E Ratio-10.505.5086.9017.12Price / Sales1.51124.191,138.53122.82Price / CashN/A15.0543.2337.84Price / Book1.433.324.804.78Net Income-$263.30M$29.98M$120.46M$225.43M7 Day Performance-1.23%0.23%-0.94%-0.82%1 Month Performance-11.88%8.46%14.81%1.02%1 Year Performance-32.76%-19.70%29.53%15.72% Myriad Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYGNMyriad Genetics4.5476 of 5 stars$13.74+0.7%$24.27+76.7%-32.8%$1.25B$823.60M-10.572,700ALKSAlkermes4.6193 of 5 stars$29.700.0%$35.42+19.2%+5.7%$4.81B$1.51B15.232,100Positive NewsFOLDAmicus Therapeutics4.3432 of 5 stars$9.78-0.2%$16.88+72.5%-27.6%$2.92B$493.67M-28.76480LGNDLigand Pharmaceuticals4.9867 of 5 stars$116.89+2.0%$147.00+25.8%+59.1%$2.21B$152.42M46.5780Analyst ForecastGERNGeron3.9644 of 5 stars$3.35-4.0%$7.15+113.4%+45.9%$2.03B$29.48M-10.47141MNKDMannKind3.2145 of 5 stars$7.00+2.2%$8.88+26.8%+95.0%$1.93B$198.96M100.00400Options VolumeAnalyst RevisionDVAXDynavax Technologies4.6664 of 5 stars$12.87+1.2%$22.00+70.9%-7.3%$1.69B$260.81M99.01408Positive NewsCLDXCelldex Therapeutics2.7043 of 5 stars$24.27-3.5%$62.25+156.5%-37.3%$1.61B$9.98M-9.44160BCRXBioCryst Pharmaceuticals3.7415 of 5 stars$7.77+2.6%$15.60+100.8%+31.0%$1.61B$412.58M-12.74530NVAXNovavax3.8666 of 5 stars$8.56-1.6%$17.83+108.3%+70.8%$1.37B$847.25M-3.791,543INVAInnoviva2.3059 of 5 stars$17.82-0.1%N/A+9.7%$1.12B$352.75M25.83112 Related Companies and Tools Related Companies ALKS Alternatives FOLD Alternatives LGND Alternatives GERN Alternatives MNKD Alternatives DVAX Alternatives CLDX Alternatives BCRX Alternatives NVAX Alternatives INVA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MYGN) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYGN Stock Alerts